Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer's disease

B P Kennedy1, M G Ziegler, M Alford

  • 1Department of Medicine, University of California, San Diego Medical Center, San Diego, CA 92103, USA. bpkennedy@ucsd.edu

Insights

Monoamine oxidase (MAO) A and B enzyme activities in Alzheimer's disease brains show early changes. MAO B increased while MAO A decreased, remaining constant as the disease progresses.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Neuropathology

Background:

  • Monoamine oxidase (MAO) A and B enzymes are implicated in Alzheimer's disease (AD) pathogenesis.
  • Elevated MAO B is found in plaque-associated glia, while increased MAO A is linked to neurotoxic metabolites and neuron loss in AD.

Purpose of the Study:

  • To investigate the relationship between cognitive function in Alzheimer's patients and post-mortem prefrontal cortex MAO A and B activities.
  • To determine if MAO A and B levels correlate with AD neuropathological markers and disease progression.

Main Methods:

  • Post-mortem prefrontal cortex tissue from 92 Alzheimer's patients and 74 controls was analyzed for MAO A and B activities using radioenzymatic methods.
  • Cognitive function was assessed using the Mini Mental Status Exam (MMSE).
  • Brain tissue was analyzed for Braak stage, plaques, tangles, and choline acetyltransferase activity.

Main Results:

  • MAO B activity was significantly increased (16%) and MAO A activity significantly decreased (17%) in Alzheimer's patients compared to controls.
  • Neither MAO A nor MAO B activities correlated with MMSE scores, choline acetyltransferase activity, plaques, tangles, Braak stage, or age of onset.
  • MAO A and B levels remained unchanged as Alzheimer's disease duration or Braak stage increased.

Conclusions:

  • Changes in MAO A and B activities in the prefrontal cortex occur early in Alzheimer's disease.
  • These enzyme activity changes appear to be stable throughout the disease progression.
  • The observed alterations in MAO A and B do not correlate with cognitive decline or neuropathological severity in Alzheimer's patients.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...